ENZON PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Enzon Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Enzon Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was $254K, a 20.9% decline year-over-year.
  • Enzon Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was $1.52M, a 47.2% increase year-over-year.
  • Enzon Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $1.37M.
  • Enzon Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$186K, a 60.3% increase from 2021.
  • Enzon Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$469K, a 64.2% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.52M $254K -$67K -20.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $1.59M $276K +$93K +50.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-05
Q1 2024 $1.5M $320K +$123K +62.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-05
Q4 2023 $1.37M $672K +$339K +102% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-20
Q3 2023 $1.03M $321K +$336K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $698K $183K +$396K Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-05
Q1 2023 $302K $197K +$488K Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-05
Q4 2022 -$186K $333K +$568K Oct 1, 2022 Dec 31, 2022 10-K 2024-03-20
Q3 2022 -$754K -$15K +$211K +93.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$965K -$213K -$194K -1021% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$771K -$291K -$302K -2745% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$469K -$235K +$191K +44.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-16
Q3 2021 -$660K -$226K +$181K +44.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$841K -$19K +$217K +91.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$1.06M $11K +$253K Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$1.31M -$426K -$164K -62.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-25
Q3 2020 -$1.15M -$407K -$82K -25.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 -$1.07M -$236K -$215K -1024% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-05
Q1 2020 -$850K -$242K +$129K +34.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-05
Q4 2019 -$979K -$262K -$7.14M -104% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-23
Q3 2019 $6.17M -$325K +$195K +37.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $5.97M -$21K +$185K +89.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-09
Q1 2019 $5.79M -$371K -$64K -20.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-09
Q4 2018 $5.85M $6.88M +$6.42M +1390% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-19
Q3 2018 -$571K -$520K -$673K -440% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $102K -$206K -$4.39M -105% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-06
Q1 2018 $4.49M -$307K -$952K -148% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-06
Q4 2017 $5.45M $462K +$5.08M Oct 1, 2017 Dec 31, 2017 10-K 2019-02-21
Q3 2017 $369K $153K -$783K -83.7% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $1.15M $4.19M +$3.15M +304% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-10
Q1 2017 -$2M $645K -$872K -57.5% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 -$1.13M -$4.61M -$17.1M -137% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-21
Q3 2016 $16M $936K +$2.75M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $13.2M $1.04M -$2.75M -72.6% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
Q1 2016 $16M $1.52M -$5.66M -78.9% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q4 2015 $21.6M $12.5M +$6.7M +115% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-24
Q3 2015 $14.9M -$1.81M -$9.41M -124% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 $24.3M $3.78M -$3.1M -45% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-10
Q1 2015 $27.4M $7.17M -$1.35M -15.8% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-09
Q4 2014 $28.8M $5.8M +$321K +5.86% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-21
Q3 2014 $28.5M $7.59M +$2.03M +36.5% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q2 2014 $26.4M $6.88M +$2.16M +45.8% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-07
Q1 2014 $24.3M $8.52M +$6.13M +257% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-13
Q4 2013 $18.2M $5.48M +$10.6M Oct 1, 2013 Dec 31, 2013 10-K 2014-03-14
Q3 2013 $7.51M $5.56M +$1.39M +33.2% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-06
Q2 2013 $6.13M $4.72M +$5.45M Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-08
Q1 2013 $678K $2.39M +$3.46M Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-09
Q4 2012 -$2.78M -$5.16M -$137K -2.73% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-14
Q3 2012 -$2.65M $4.18M +$13.3M Jul 1, 2012 Sep 30, 2012 10-K 2014-03-14
Q2 2012 -$15.9M -$729K +$6.34M +89.7% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-14
Q1 2012 -$22.3M -$1.07M -$1.5M -348% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-14
Q4 2011 -$20.8M -$5.02M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-18
Q3 2011 -$9.11M -$751K -8.99% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-18
Q2 2011 -$7.07M -$1.45M -25.7% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-18
Q1 2011 $431K Jan 1, 2011 Mar 31, 2011 10-K 2013-03-18
Q3 2010 -$8.35M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-04
Q2 2010 -$5.62M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.